Carbidopa
- Generic Name
- Carbidopa
- Brand Names
- Dhivy, Duodopa, Duopa, Lodosyn, Parcopa, Rytary, Sinemet, Stalevo
- Drug Type
- Small Molecule
- Chemical Formula
- C10H14N2O4
- CAS Number
- 28860-95-9
- Unique Ingredient Identifier
- KR87B45RGH
- Background
Carbidopa presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate. It potently inhibits aromatic amino acid decarboxylase (DDC) and due to its chemical properties, it does not cross the blood-brain barrier. Due to its activity, carbidopa is always administered concomitantly with levodopa. An individual formulation containing...
- Indication
Carbidopa is indicated with levodopa for the treatment of symptoms of idiopathic Parkinson disease, postencephalitic parkinsonism and symptomatic parkinsonism followed by carbon monoxide or manganese intoxication.
The combination therapy is administered for the reduction of levodopa-driven nausea and vomiting.
...
- Associated Conditions
- Parkinson's Disease (PD), Parkinsonism post encephalitic, Symptomatic Parkinson Disease, Levodopa-driven nausea and vomiting
- Associated Therapies
- -
TrueBinding Receives FDA IND Go Ahead for Parkinson's Phase 2A Clinical Trial
TrueBinding, Inc. received FDA IND approval for TB006, a monoclonal antibody targeting Galectin-3, potentially modifying Parkinson’s Disease. TB006, delivered via monthly IV infusion, aims to neutralize Galectin-3, dissociate neurotoxic oligomers, and repair intracellular lysosomes. A Phase 2A trial will evaluate TB006's safety and efficacy in early to mild Parkinson’s patients, with an estimated primary completion date in Q1 2026.
Earnings call: Amneal Pharmaceuticals sees a 13% revenue surge in Q3 2024
Amneal Pharmaceuticals reported a 13% increase in Q3 revenue to $702 million, driven by strong performance in generics and specialty products. The company launched CREXONT for Parkinson's disease and partnered with Metsera for obesity treatments, positioning it for growth. Amneal plans to build two new facilities in India and expand its biosimilar portfolio, projecting healthcare distribution revenues to exceed $700 million by 2025 and international expansion to add $50-100 million in revenue by 2027.
Evecxia Therapeutics Announces Successful Completion of Pre-IND Meeting with the FDA
Evecxia Therapeutics completed a pre-IND meeting with the FDA, receiving no concerns on non-clinical or clinical safety data for EVX-101, a novel adjunctive antidepressant. The meeting provided a clear path for filing an IND to conduct a Phase 2 trial in depression patients not responding adequately to standard care.
AbbVie gets continuous Parkinson's drug over the line in US
AbbVie's Vyalev, a subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson's, has received FDA approval after a 18-month delay. Vyalev, delivered via a pump, aims to control motor fluctuations better than oral therapies and is expected to be covered by Medicare from the second half of 2025. The drug is already available in the EU under the name Produodopa and has been endorsed for NHS use in England and Wales.
AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev
FDA approves AbbVie's Vyalev, a subcutaneous drug for advanced Parkinson's disease, after two prior rejections. Vyalev is the first 24-hour continuous levodopa-based therapy, already launched in 34 countries. AbbVie plans to use data from four clinical studies for tavapadon, acquired through the Cerevel Therapeutics deal, to seek further regulatory approvals.
AbbVie levodopa therapy approved as Vyalev for advanced Parkinson's
FDA approves Vyalev, a 24-hour subcutaneous levodopa/carbidopa infusion for advanced Parkinson’s, aiming to reduce off episodes. Available in Canada, EU, and U.K., U.S. access depends on insurance, with Medicare coverage expected in 2H 2025. Vyalev's approval was based on Phase 3 trial results showing significant reduction in off time compared to oral therapy.
Related Clinical Trials:
AbbVie's continuous Parkinson's disease therapy Vyalev approved by FDA
AbbVie’s Vyalev, a 24-hour continuous subcutaneous infusion of foscarbidopa and foslevodopa, approved by FDA for treating motor fluctuations in advanced Parkinson’s disease. Vyalev showed superior improvement in 'on' time without troublesome dyskinesia and decreased 'off' time compared to oral CD/LD in clinical trials.
Continuous Parkinson's Disease Therapy Wins FDA Nod
FDA approves subcutaneous 24-hour infusion of foscarbidopa and foslevodopa (Vyalev) for advanced Parkinson's, offering continuous levodopa delivery. The approval is based on a phase III trial showing increased 'on' time and decreased 'off' time compared to oral treatment, with common adverse reactions including infusion site events, hallucinations, and dyskinesia.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath